Pomalidomide-PEG2-butyl iodide

 CAS No.: 1835705-72-0  Cat No.: BP-100038  Purity: ≥98% 4.5  

Pomalidomide-PEG2-butyl iodide is a high-quality E3 Ligase Ligand-Linker Conjugate designed specifically for PROTAC (Proteolysis Targeting Chimera) research and drug development. This compound features pomalidomide, a well-established ligand for the CRBN (cereblon) E3 ubiquitin ligase, linked via a flexible PEG2 spacer to a butyl iodide functional group, making it ideal for coupling with various target protein ligands. As a PROTAC intermediate, Pomalidomide-PEG2-butyl iodide enables researchers to efficiently design and synthesize bifunctional molecules that harness the cell's ubiquitin-proteasome system for selective protein degradation. Its versatile structure supports the rapid development of next-generation therapeutics targeting disease-related proteins, including those implicated in cancer, neurodegeneration, and other pathologies. This product is an essential tool for medicinal and chemical biology researchers pioneering targeted protein degradation strategies.

Pomalidomide-PEG2-butyl iodide

Structure of 1835705-72-0

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C23H28IN3O7
Molecular Weight
585.39

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
≥98%
ShelfLife
2 years
Storage
-20°C
Synonyms
N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-2-(2-((6-iodohexyl)oxy)ethoxy)acetamide

Background Introduction

Pomalidomide-PEG2-butyl iodide is a specialized E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras). Pomalidomide acts as a cereblon (CRBN) E3 ligase ligand, while the PEG2 (polyethylene glycol spacer) and butyl iodide group offer enhanced solubility and chemical versatility for coupling to various target protein ligands. This makes Pomalidomide-PEG2-butyl iodide an optimal choice for researchers seeking to develop next-generation protein degraders.

Mechanism

The mechanism of action of Pomalidomide-PEG2-butyl iodide is rooted in its role as a E3 ligase ligand within bifunctional PROTAC molecules. The pomalidomide moiety selectively binds to the cereblon (CRBN) E3 ubiquitin ligase complex. The PEG2 linker provides spatial flexibility and improved solubility, while the terminal butyl iodide group acts as a reactive handle for chemical conjugation. Upon incorporation into a PROTAC, this conjugate facilitates the recruitment of the E3 ligase to a target protein, leading to polyubiquitination and subsequent proteasomal degradation of the target protein within cells.

Applications

Pomalidomide-PEG2-butyl iodide is widely used as a chemical scaffold in the construction of custom PROTAC molecules. Its applications include the targeted degradation of disease-associated proteins in cancer biology, neurodegenerative disorders, and drug discovery research. This conjugate enables researchers to efficiently design and synthesize protein degraders with tailored selectivity and potency. It is also valuable for generating tool compounds to investigate protein function, validate therapeutic targets, and accelerate the development of novel protein degradation-based drugs.

• PEGylated linker improves solubility and pharmacokinetic properties for enhanced PROTAC performance.
• Alkyl iodide functional group enables versatile conjugation to a variety of target ligands in E3 ligase-based PROTAC design.
1. Iodide Binding in Sodium-Coupled Cotransporters
Ariela Vergara-Jaque, Peying Fong, Jeffrey Comer J Chem Inf Model. 2017 Dec 26;57(12):3043-3055.doi: 10.1021/acs.jcim.7b00521.Epub 2017 Dec 4.
Several apical iodide translocation pathways have been proposed for iodide efflux out of thyroid follicular cells, including a pathway mediated by the sodium-coupled monocarboxylate transporter 1 (SMCT1), which remains controversial. Herein, we evaluate structural and functional similarities between SMCT1 and the well-studied sodium-iodide symporter (NIS) that mediates the first step of iodide entry into the thyroid. Free-energy calculations using a force field with electronic polarizability verify the presence of a conserved iodide-binding pocket between the TM2, TM3, and TM7 segments in hNIS, where iodide is coordinated by Phe67, Gln72, Cys91, and Gln94. We demonstrate the mutation of residue Gly93 of hNIS to a larger amino acid expels the side chain of a critical tryptophan residue (Trp255) into the interior of the binding pocket, partially occluding the iodide binding site and reducing iodide affinity, which is consistent with previous reports associating mutation of this residue with iodide uptake deficiency and hypothyroidism. Furthermore, we find that the position of Trp255 in this hNIS mutant mirrors that of Trp253 in wild-type hSMCT1, where a threonine (Thr91) occupies the position homologous to that occupied by glycine in wild-type hNIS (Gly93). Correspondingly, mutation of Thr91 to glycine in hSMCT1 makes the pocket structure more like that of wild-type hNIS, increasing its iodide affinity. These results suggest that wild-type hSMCT1 in the inward-facing conformation may bind iodide only very weakly, which may have implications for its ability to transport iodide.
2. Cathodic stripping voltammetric determination of iodide using disposable sensors
Hugo Cunha-Silva, M Julia Arcos-Martinez Talanta. 2019 Jul 1;199:262-269.doi: 10.1016/j.talanta.2019.02.061.Epub 2019 Feb 16.
The World Health Organization considers iodide deficiency diseases (IDD) to be a public health problem. The main indicator to access IDD is urinary iodide, since approximately 90% of the ingested iodide uses this clearance path, with urine being a preferable target for the analysis. In this work, two screen-printed carbon electrode (SPCE) based sensors were developed to determine iodide by using only a single drop of sample. A first approach based on a SPCE proves to selectively determine iodide through the control of the cathodic stripping voltammetric (CSV) parameters. However, this strategy exhibits a gap in determining trace iodide concentrations, which is improved by modifying the working electrode surface with a chitosan coating. The performance of this new CS/SPCE-based sensor was compared with that of the previous SPCE-based sensor, showing improved iodide determination sensitivity. A limit of detection of 1.0 × 10-8 M and a linear analysis range of 0.15-500 µM were achieved with this sensor. The application of both sensors to real-life samples found values close to those determined by the standard Sandell-Kolthoff spectrophotometric method, proving them to be powerful analytical tools for iodide determination in different kinds of samples, including biological matrices.
3. Catalytic, Enantioselective 1,2-Difluorination of Cinnamamides
Moriana K Haj, Steven M Banik, Eric N Jacobsen Org Lett. 2019 Jul 5;21(13):4919-4923.doi: 10.1021/acs.orglett.9b00938.Epub 2019 Apr 9.
The enantio- and diastereoselective synthesis of 1,2-difluorides via chiral aryl iodide-catalyzed difluorination of cinnamamides is reported. The method uses HF-pyridine as a fluoride source and mCPBA as a stoichiometric oxidant to turn over catalyst, and affords compounds containing vicinal, fluoride-bearing stereocenters. Selectivity for 1,2-difluorination versus a rearrangement pathway resulting in 1,1-difluorination is enforced through anchimeric assistance from a N- tert-butyl amide substituent.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket